Abstract
Mycolic acids are the major lipid components of the unique mycobacterial cell wall responsible for the protection of the tuberculosis bacilli from many outside threats. Mycolic acids are synthesized in the cytoplasm and transported to the outer membrane as trehalose- containing glycolipids before being esterified to the arabinogalactan portion of the cell wall and outer membrane glycolipids. The large size of these unique fatty acids is a result of a huge metabolic investment that has been evolutionarily conserved, indicating the importance of these lipids to the mycobacterial cellular survival. There are many key enzymes involved in the mycolic acid biosynthetic pathway, including fatty acid synthesis (KasA, KasB, MabA, InhA, HadABC), mycolic acid modifying enzymes (SAM-dependent methyltransferases, aNAT), fatty acid activating and condensing enzymes (FadD32, Acc, Pks13), transporters (MmpL3) and tranferases (Antigen 85A-C) all of which are excellent potential drug targets. Not surprisingly, in recent years many new compounds have been reported to inhibit specific portions of this pathway, discovered through both phenotypic screening and target enzyme screening. In this review, we analyze the new and emerging inhibitors of this pathway discovered in the post-genomic era of tuberculosis drug discovery, several of which show great promise as selective tuberculosis therapeutics.
Keywords: Tuberculosis, antituberculosis agents, mycolic acid, fatty acid synthase, KasA, KasB, MabA, HadABC, InhA, FadD32, Pks13, MmpL3, antigen 85.
Current Pharmaceutical Design
Title:New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics
Volume: 20 Issue: 27
Author(s): E. Jeffrey North, Mary Jackson and Richard E. Lee
Affiliation:
Keywords: Tuberculosis, antituberculosis agents, mycolic acid, fatty acid synthase, KasA, KasB, MabA, HadABC, InhA, FadD32, Pks13, MmpL3, antigen 85.
Abstract: Mycolic acids are the major lipid components of the unique mycobacterial cell wall responsible for the protection of the tuberculosis bacilli from many outside threats. Mycolic acids are synthesized in the cytoplasm and transported to the outer membrane as trehalose- containing glycolipids before being esterified to the arabinogalactan portion of the cell wall and outer membrane glycolipids. The large size of these unique fatty acids is a result of a huge metabolic investment that has been evolutionarily conserved, indicating the importance of these lipids to the mycobacterial cellular survival. There are many key enzymes involved in the mycolic acid biosynthetic pathway, including fatty acid synthesis (KasA, KasB, MabA, InhA, HadABC), mycolic acid modifying enzymes (SAM-dependent methyltransferases, aNAT), fatty acid activating and condensing enzymes (FadD32, Acc, Pks13), transporters (MmpL3) and tranferases (Antigen 85A-C) all of which are excellent potential drug targets. Not surprisingly, in recent years many new compounds have been reported to inhibit specific portions of this pathway, discovered through both phenotypic screening and target enzyme screening. In this review, we analyze the new and emerging inhibitors of this pathway discovered in the post-genomic era of tuberculosis drug discovery, several of which show great promise as selective tuberculosis therapeutics.
Export Options
About this article
Cite this article as:
North Jeffrey E., Jackson Mary and Lee E. Richard, New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118203641
DOI https://dx.doi.org/10.2174/1381612819666131118203641 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptide-Mediated Delivery of Therapeutic and Imaging Agents Into Mammalian Cells
Current Pharmaceutical Design Using NMR to Develop New Allosteric and Allo-Network Drugs
Current Drug Discovery Technologies Foreword (“New Targets and New Drugs: from in silico Planning to in vivo Testing”)
Current Pharmaceutical Biotechnology Exploring Interaction of TNF and Orthopoxviral CrmB Protein by Surface Plasmon Resonance and Free Energy Calculation
Protein & Peptide Letters Glycosylation Employing Unprotected Carbohydrate Acceptor Components
Current Organic Chemistry Investigation of Potential Inhibitors of Chorismate-Utilizing Enzymes
Current Medicinal Chemistry Resistant Tuberculosis: the Latest Advancements of Second-line Antibiotic Inhalation Products
Current Pharmaceutical Design Chest X-ray in Sarcoidosis: The Association of Age, Gender, and Ethnicity with Different Radiological Findings
Current Respiratory Medicine Reviews Biomarker Metabolite Signatures Pave the Way for Electronic-nose Applications in Early Clinical Disease Diagnoses
Current Metabolomics Study of the Scientific Production on Leishmaniasis in Latin America
Recent Patents on Anti-Infective Drug Discovery Dysprosium Hydroxide Nanowires Modified Electrode for Determination of Rifampicin Drug in Human Urine and Capsules by Adsorptive Square Wave Voltammetry
Current Pharmaceutical Analysis Role of Fas-Ligand Induced Apoptosis in Pulmonary Inflammation and Injury
Current Drug Targets - Inflammation & Allergy Invasive Pulmonary Aspergillosis in Acute Leukemia: Current Issues for Pathogenesis, Diagnosis and Treatment
Current Respiratory Medicine Reviews Anti-Tubercular Agents from <i>Glycyrrhiza</i> glabra
Current Topics in Medicinal Chemistry ent-Abietane Lactones from Euphorbia
Mini-Reviews in Medicinal Chemistry Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Comparative Proteome Analysis of <i>Mycobacterium Tuberculosis</i> Strains - H37Ra, H37Rv, CCDC5180, and CAS/NITR204: A Step Forward to Identify Novel Drug Targets
Letters in Drug Design & Discovery